Risk factors and growth factors in ROP

Early Human Development

Volumn 85, Issue 10 SUPPL., 2009, Pages

  Romagnoli, C ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Blood transfusion; Infection; Retinopathy of prematurity; Vascular growth factors

Indexed keywords

OXYGEN; SOMATOMEDIN C; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; BIRTH WEIGHT; BLOOD TRANSFUSION; GESTATIONAL AGE; HUMAN; METABOLISM; NEWBORN; PATHOLOGY; RETROLENTAL FIBROPLASIA; RISK FACTOR; TIME;

BIRTH WEIGHT; BLOOD TRANSFUSION; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR I; OXYGEN; RETINOPATHY OF PREMATURITY; RISK FACTORS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 76249101989     PISSN: 03783782     EISSN: 18726232     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2009.08.026     Document Type: Article

References (58)

1. Chen J., Smith L.E.H. Retinopathy of prematurity. Angiogenesis 2007, 10:133-140.
2. Blair B.M., O'halloran H.S., Pauly T.H., Stevens J.L. Decreased incidence of retinopathy of prematurity, 1995-1997. J AAPOS 2001, 5:118-122.
3. Bullard S.R., Donahue S.P., Feman S.S., Sinatra B.B., Walsh W.F. The decreasing incidence and severity of retinopathy of prematurity. J AAPOS 1999, 3:46-52.
4. Giannantonio C., Papacci P., Molle F., Lepore D., Gallini F., Romagnoli C. An epidemiologic analysis of retinopathy of prematurity over 10years. J Pediatr Ophthalmol Strabismus 2008, 45:162-167.
5. Todd D.A., Wright A., Smith J., the NICUS Group Severe retinopathy of prematurity in infants ,30weeks' gestation in New South Wales and the Australian Capital Territory from 1992 to 2002. Arch Dis Child Fetal Neonatal Ed 2007, 92:F251-F254.
6. Hellstrom A., Engstrom E., Hard A.-L., Albertsson-Wikland K., Carlsson B., Niklasson A., et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003, 112:1016-1020.
7. Smith L.E.H. Pathogenesis of retinopathy of prematurity. Semin Neonatol 2003, 8:469-473.
8. Pierce E.A., Foley E.D., Smith L.E.H. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996, 114:1219-1228.
9. Alon T., Hemo I., Itin A., Pe'er J., Stone J., Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995, 1:1024-1028.
10. Hellstrom A., Perruzzi C., Ju M., Engstrom E., Hard A.L., Liu J.L., et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 2001, 98:5804-5808.
11. Mintz-Hittner H.A., Kuffel R.R. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008, 28:831-838.
12. Chung E.J., Kim J.H., Ahn H.S., Koh H.J. Combination of laser photocoagulation and intravitreal bevacizumab(avastin) for aggressive zone 1 ROP. Graefe's Arch Clin Exp Ophthalmol 2007, 245:1727-1730.
13. Kusaka S., Shima C., Wada K., Arahori H., Shimojyo H., Sato T., et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity a pilot study. Br J Ophthalmol 2008, 92:1450-1455.
14. Lalwani G.A., Berrocal A.M., Murray T.G., Buch M., Cardone S., Hess D., et al. Off-label use of intravitreal Bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008, 28:S13-S18.
15. Quiroz-Mercado H., Martinez-Castellanos M.A., Hrnandez-Rojas M.L., Salazar-Teran N., Chan R.V.P. Antiangiogenic therapy with intravitreal Bevacizumab for retinopathy of prematurity. Retina 2008, 28:S19-S25.
16. Hellstrom A., Carlsson B., Niklasson A., Segnestam K., Boguszewski M., de Lacereda L., et al. IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab 2002, 87:3413-3416.
17. Smith L.E.H. IGF-1 and retinopathy of prematurity in the preterm infants. Biol Neonate 2005, 88:237-244.
18. Lofqvist C., Engstrom E., Sigurdsson J., Hard A.-L., Niklasson A., Ewald U., et al. Postnatal head growth among premature infants parallels retinopathy of prematurity and insulin-like growth factor-1 deficit. Pediatrics 2006, 117:1930-1938.
19. Wang H.S., Chard T. The role of insulin-like growth factor-I and insulin-like growth factor-binding protein-1 in the control of human fetal growth. J Endocrinol 1992, 132:11-19.
20. Langford K., Nicolaides K., Miell J.P. Maternal and fetal insulin-like growth factors and their binding proteins in the second and third trimesters of human pregnancy. Human Reprod 1998, 13:1389-1393.
21. Bocconi L., Mauro F., Maddalena S.E., De Iulio C., Tirelli A.S., Pace E., et al. Insulinlike growth factor 1 in controls and growth-retarded fetuses. Fetal Diagn Ther 1998, 13:192-196.
22. Giudice L.C., de Zegher F., Gargosky S.E., Dsupin B.A., de las Fuentes L., Crystal R.A., et al. Insulin-like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremis of intrauterina growth. J Clin Endocrinol Metab 1995, 80:1548-1555.
23. Ostlund E., Bang P., Hagenas L., Fried G. Insulin-like growth factor I in fetal serum obtained by cordocentesis is correlated with intrauterine growth retardation. Human Reprod 1997, 12:840-844.
24. Engstrom E., Niklasson A., Wikland K.A., Ewald U., Hellstrom A. The role of maternal factors, postnatal nutrition, weight gain, and gender in regulation of serum IGF-I among preterm infants. Pediatr Res 2005, 57:605-610.
25. Kim W.K., Ryu Y.H., Seo D.S., Lee C.Y., Ko Y. Effects of oral administration of insulin-like growth factor-I on circulating concentration of insulin-like growth factor-I and growth of internal organs in weanling mice. Biol Neonate 2006, 89:199-204.
26. Kimura T., Murakawa Y., Ohno M., Ohtani S., Higaki K. Gastrointestinal absorption of recombinant human insulin-like growth factor-I in rats. J Pharmacol Exp Ther 1997, 283:611-618.
27. Yoon H.Z., Yan Y., Geng Y., Higgins R.D. Neuropeptide Y expression in a mouse model of oxygen-induced retinopathy. Clin Exper Ophthalmol 2002, 30:424-428.
28. Sarlos S., Rizkalla B., Moravzki C.J., Cao Z., Cooper M.E., Wilkinson-Berka J.L. Retinal angiogenesis is mediated by an interaction between the angiotensin Type 2 receptor, VEGF and angiopoietin. Am J Pathol 2003, 163:879-887.
29. Ohno-Matsui K., Uetama T., Yoshida T., Hayano M., Itoh T., Morita I., et al. Reduced retinal angiogenesis in MMP-2-deficient mice. Invest Ophthalmol Vis Sci 2003, 44:5370-5375.
30. Morita M., Ohaned O., Yamashita T., Takahashi S., Suzuku N., Nakajima O., et al. HLF/HIF-2a is a key factor in retinopathy of prematurity in association with erithropoietin. EMBO J 2003, 22:1134-1146.
31. Miyamoto N., Mandai M., Takagi H., Suzuma I., Suzuma K., Koyama S., et al. Contrasting effect of estrogen on VEGF induction under different oxygen status and its role in murine ROP. Invest Ophthalmol Vis Sci 2002, 43:2007-2014.
32. Duenas Z., Rivera J.C., Quiroz-Mercado H., Aranda J., Macotela Y., Montes de Oca P., et al. Prolactin in eyes of patients with retinopathy of prematurity: implications for vascular regression. Invest Ophthalmol Vis Sci 2004, 45:2049-2055.
33. Tamura M., Sebastian S., Gurates B., Yang S., Fang Z., Bulun S.E. Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells. J Clin Endocrinol Metab 2002, 87:3504-3507.
34. Wilkinson-Berka J.L., Alousis N.S., Kelly D.J., Gilbert R.E. Angiogenesis in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2003, 44:974-979.
35. Giannantonio C, Papacci P, Purcaro V, Fioretti M, Tesfagabir GM, Molle F, et al. Ketorolac effectiveness in prevention severe retinopathy of prematurity. JAAPOS, in press.
36. Liu P.M., Fang P.C., Huang C.B., Kou H.K., Chung M.Y., Yang Y.H., et al. Risk factors of retinopathy of prematurity in premature infants weighing less than 1600g. Am J Perinatol 2005, 22:115-120.
37. Darlow B.A., Hutchinson J.L., Henderson-Smart D.J., Donohue D.A., Simpson J.M., Evans N.J. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics 2005, 115:990-996.
38. Flynn J.T., Bancalari E., Snyder E.S., Goldberg R.N., Feuer W., Cassady J., et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 1992, 326:1050-1054.
39. James L.S., Lanman J.T. History of oxygen therapy and retrolental fibroplasia. Pediatrics 1976, 57(suppl):591-642.
40. Flynn J.T., Bancalari E., Snyder E.S., Goldberg R.N., Feuer W., Cassady J., et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 1992, 326:1050-1054.
41. Tin W., Wariyar U. Giving small babies oxygen: 50years of uncertainty. Semin Neonatol 2002, 7:361-367.
42. Chow L.C., Wright K.W., Sola A., the CSMC Oxygen Administration Study Group Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants?. Pediatrics 2003, 111:339-345.
43. Ertl T., Gyarmati J., Gaal V., Szabo I. Relationship between hyperglycemia and retinopathy of prematurity in very low birth weight infants. Biol Neonate 2006, 89:56-59.
44. Manzoni P., Maestri A., Leonessa M., Mostert M., Farina D., Gomirato G., et al. Fungal and bacterial sepsis and threshold ROP in preterm very low birth weight neonates. J Perinatol 2006, 26:23-30.
45. Bharwani S.K., Dhanireddy R. Systemic fungal infection is associated with the development of retinopathy of prematurity in very low birth weight infants: a meta-review. J Perinatol 2008, 28:61-66.
46. Phelps D.L., Watts J.L. Early light reduction for preventing retinopathy of prematurity in very low birth weight infants. Cochrane Database Syst Rev 2001, (1):CD 000122.
47. Braz R.R.T., Moreira M.E.L., de Carvalho M., Lopes J.M.A., Rodrigues M.A., Cabral J.A.O., et al. Effect of light reduction on the incidence of retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed 2006, 91:F443-F444.
48. Lang D.M., Blackledge J., Arnold R.W. Is Pacific race a retinopathy of prematurity risk factor?. Arch Pediatr Adolesc Med 2005, 159:771-773.
49. Bizzarro M.J., Hussain N., Jonsson B., Feng R., Ment L.R., Gruen J.R., et al. Genetic susceptibility to retinopathy of prematurity. Pediatrics 2006, 118:1858-1863.
50. Mohamed S., Schaa K., Cooper M.E., Ahrens E., Alvarado A., Colaizy T., et al. Genetic contributions to the development of retinopathy of prematurity. Pediatr Res 2009, 65:193-197.
51. Clark C., Gibbs J.A., Maniello R., Outerbridge E.W., Aranda J.V. Blood transfusion: a possible risk factor in retrolental fibroplasia. Acta Paediatr Scand 1981, 70:535-539.
52. Cooke R.W.I., Clark D., Hickey-Dwyer M., Weindling A.M. The apparent role of blood transfusions in the development of retinopathy of prematurity. Eur J Pediatr 1993, 152:833-836.
53. Hesse L., Eberl W., Schlaud M., Poets C.F. Blood transfusion: iron load and retinopathy of prematurity. Eur J Pediatr 1997, 156:465-470.
54. Romagnoli C., Girlando P., Zecca E., De Carolis M.P., Papacci P., Tortorolo G. Emotrasfusioni e retinopatia della prematurità. Riv Ital Pediatr 1999, 25:879-882.
55. Sullivan J.L. Iron, plasma antioxidants, and the "oxygen radical disease of prematurity". Am J Dis Child 1988, 142:1341-1344.
56. Hirano K., Morinobu T., Kim H., Hiroi M., Ban R., Ogawa S., et al. Blood transfusion increases radical promoting non-transferrin bound iron in preterm infants. Arch Dis Child Fetal Neonatal Ed 2001, 84(3):F188-F193.
57. Scott P.H., Berger H.M., Kenward C., Scott P., Wharton B.A. Effect of gestational age and intrauterine nutrition on plasma transferrin and iron in the newborn. Arch Dis Child 1975, 50:796-798.
58. Hübler A., Knote K., Kauf E., Barz D., Schlenvoigt D., Schramm D. Does insulin-like growth factor 1 contribute in red blood cell transfusions to the pathogenesis of retinopathy of prematurity during retinal neovascularization?. Biol Neonate 2006, 89:92-98.